Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia.
Identifieur interne : 000C81 ( Main/Exploration ); précédent : 000C80; suivant : 000C82Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia.
Auteurs : Jaime Mcdonald [Canada] ; Philippe Corbeil ; Emmanuelle PourcherSource :
- The American journal of geriatric pharmacotherapy [ 1876-7761 ] ; 2011.
Descripteurs français
- KwdFr :
- Antidépresseurs de seconde génération (effets indésirables), Antidépresseurs de seconde génération (usage thérapeutique), Antiparkinsoniens (administration et posologie), Antiparkinsoniens (usage thérapeutique), Association de médicaments (MeSH), Chlorhydrate de venlafaxine (MeSH), Cyclohexanols (administration et posologie), Cyclohexanols (usage thérapeutique), Diagnostic assisté par ordinateur (MeSH), Démence vasculaire (physiopathologie), Démence vasculaire (traitement médicamenteux), Femelle (MeSH), Humains (MeSH), Lévodopa (administration et posologie), Lévodopa (usage thérapeutique), Microvaisseaux (MeSH), Paroxétine (effets indésirables), Paroxétine (usage thérapeutique), Sujet âgé de 80 ans ou plus (MeSH), Équilibre postural (effets des médicaments et des substances chimiques), Études de suivi (MeSH).
- MESH :
- administration et posologie : Antiparkinsoniens, Cyclohexanols, Lévodopa.
- effets des médicaments et des substances chimiques : Équilibre postural.
- effets indésirables : Antidépresseurs de seconde génération, Paroxétine.
- physiopathologie : Démence vasculaire.
- traitement médicamenteux : Démence vasculaire.
- usage thérapeutique : Antidépresseurs de seconde génération, Antiparkinsoniens, Cyclohexanols, Lévodopa, Paroxétine.
- Association de médicaments, Chlorhydrate de venlafaxine, Diagnostic assisté par ordinateur, Femelle, Humains, Microvaisseaux, Sujet âgé de 80 ans ou plus, Études de suivi.
English descriptors
- KwdEn :
- Aged, 80 and over (MeSH), Antidepressive Agents, Second-Generation (adverse effects), Antidepressive Agents, Second-Generation (therapeutic use), Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Cyclohexanols (administration & dosage), Cyclohexanols (therapeutic use), Dementia, Vascular (drug therapy), Dementia, Vascular (physiopathology), Diagnosis, Computer-Assisted (MeSH), Drug Therapy, Combination (MeSH), Female (MeSH), Follow-Up Studies (MeSH), Humans (MeSH), Levodopa (administration & dosage), Levodopa (therapeutic use), Microvessels (MeSH), Paroxetine (adverse effects), Paroxetine (therapeutic use), Postural Balance (drug effects), Venlafaxine Hydrochloride (MeSH).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Cyclohexanols, Levodopa.
- chemical , adverse effects : Antidepressive Agents, Second-Generation, Paroxetine.
- chemical , therapeutic use : Antidepressive Agents, Second-Generation, Antiparkinson Agents, Cyclohexanols, Levodopa, Paroxetine.
- drug effects : Postural Balance.
- drug therapy : Dementia, Vascular.
- physiopathology : Dementia, Vascular.
- Aged, 80 and over, Diagnosis, Computer-Assisted, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Microvessels, Venlafaxine Hydrochloride.
Abstract
BACKGROUND
Postural instability is a concern in several neurologic conditions and also among the elderly. Dysfunction in serotonergic, noradrenergic, and dopaminergic pathways may be involved in the etiology of postural imbalance.
OBJECTIVE
The objective of this case report was to quantify, using computerized posturography, substitution with venlafaxine, and later levodopa, in a suspected case of postural instability with paroxetine.
CASE SUMMARY
Presented is an 86-year-old woman with frequent falls and a Parkinson-like syndrome of the lower limbs secondary to microvascular dementia. Paroxetine was gradually discontinued and exchanged for venlafaxine, 37.5 mg twice daily. Before and after medication changes, static posturography was performed under eyes open and closed conditions. Following 3 months of venlafaxine, the patient showed significant improvement from baseline, however, venlafaxine was then reduced to 37.5 mg at bedtime. Six months later, levodopa was introduced and further improvement was observed. It is possible that venlafaxine, which maintains a more balanced affinity for serotonin and norepinephrine transporters, may have provided postural benefit. Decreased sedation secondary to venlafaxine reduction may have elicited further improvements in addition to the increased lower limb functionality observed with levodopa.
CONCLUSIONS
For patients on antidepressants, switching medications may be worthwhile in those with balance problems. The prudent addition of medications may also be an option.
DOI: 10.1016/j.amjopharm.2011.03.002
PubMed: 21507731
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia.</title><author><name sortKey="Mcdonald, Jaime" sort="Mcdonald, Jaime" uniqKey="Mcdonald J" first="Jaime" last="Mcdonald">Jaime Mcdonald</name><affiliation wicri:level="4"><nlm:affiliation>Groupe de recherche en analyse du mouvement etergonomie, Kinesiology, Laval University, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Groupe de recherche en analyse du mouvement etergonomie, Kinesiology, Laval University, Québec</wicri:regionArea><orgName type="university">Université Laval</orgName><placeName><settlement type="city">Québec (ville)</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Corbeil, Philippe" sort="Corbeil, Philippe" uniqKey="Corbeil P" first="Philippe" last="Corbeil">Philippe Corbeil</name></author><author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21507731</idno><idno type="pmid">21507731</idno><idno type="doi">10.1016/j.amjopharm.2011.03.002</idno><idno type="wicri:Area/Main/Corpus">000C49</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C49</idno><idno type="wicri:Area/Main/Curation">000C49</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000C49</idno><idno type="wicri:Area/Main/Exploration">000C49</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia.</title><author><name sortKey="Mcdonald, Jaime" sort="Mcdonald, Jaime" uniqKey="Mcdonald J" first="Jaime" last="Mcdonald">Jaime Mcdonald</name><affiliation wicri:level="4"><nlm:affiliation>Groupe de recherche en analyse du mouvement etergonomie, Kinesiology, Laval University, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Groupe de recherche en analyse du mouvement etergonomie, Kinesiology, Laval University, Québec</wicri:regionArea><orgName type="university">Université Laval</orgName><placeName><settlement type="city">Québec (ville)</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Corbeil, Philippe" sort="Corbeil, Philippe" uniqKey="Corbeil P" first="Philippe" last="Corbeil">Philippe Corbeil</name></author><author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name></author></analytic><series><title level="j">The American journal of geriatric pharmacotherapy</title><idno type="eISSN">1876-7761</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged, 80 and over (MeSH)</term><term>Antidepressive Agents, Second-Generation (adverse effects)</term><term>Antidepressive Agents, Second-Generation (therapeutic use)</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Cyclohexanols (administration & dosage)</term><term>Cyclohexanols (therapeutic use)</term><term>Dementia, Vascular (drug therapy)</term><term>Dementia, Vascular (physiopathology)</term><term>Diagnosis, Computer-Assisted (MeSH)</term><term>Drug Therapy, Combination (MeSH)</term><term>Female (MeSH)</term><term>Follow-Up Studies (MeSH)</term><term>Humans (MeSH)</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Microvessels (MeSH)</term><term>Paroxetine (adverse effects)</term><term>Paroxetine (therapeutic use)</term><term>Postural Balance (drug effects)</term><term>Venlafaxine Hydrochloride (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antidépresseurs de seconde génération (effets indésirables)</term><term>Antidépresseurs de seconde génération (usage thérapeutique)</term><term>Antiparkinsoniens (administration et posologie)</term><term>Antiparkinsoniens (usage thérapeutique)</term><term>Association de médicaments (MeSH)</term><term>Chlorhydrate de venlafaxine (MeSH)</term><term>Cyclohexanols (administration et posologie)</term><term>Cyclohexanols (usage thérapeutique)</term><term>Diagnostic assisté par ordinateur (MeSH)</term><term>Démence vasculaire (physiopathologie)</term><term>Démence vasculaire (traitement médicamenteux)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Lévodopa (administration et posologie)</term><term>Lévodopa (usage thérapeutique)</term><term>Microvaisseaux (MeSH)</term><term>Paroxétine (effets indésirables)</term><term>Paroxétine (usage thérapeutique)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Équilibre postural (effets des médicaments et des substances chimiques)</term><term>Études de suivi (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Cyclohexanols</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antidepressive Agents, Second-Generation</term><term>Paroxetine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents, Second-Generation</term><term>Antiparkinson Agents</term><term>Cyclohexanols</term><term>Levodopa</term><term>Paroxetine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiparkinsoniens</term><term>Cyclohexanols</term><term>Lévodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Postural Balance</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dementia, Vascular</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Équilibre postural</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antidépresseurs de seconde génération</term><term>Paroxétine</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Démence vasculaire</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dementia, Vascular</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Démence vasculaire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antidépresseurs de seconde génération</term><term>Antiparkinsoniens</term><term>Cyclohexanols</term><term>Lévodopa</term><term>Paroxétine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged, 80 and over</term><term>Diagnosis, Computer-Assisted</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Microvessels</term><term>Venlafaxine Hydrochloride</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association de médicaments</term><term>Chlorhydrate de venlafaxine</term><term>Diagnostic assisté par ordinateur</term><term>Femelle</term><term>Humains</term><term>Microvaisseaux</term><term>Sujet âgé de 80 ans ou plus</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Postural instability is a concern in several neurologic conditions and also among the elderly. Dysfunction in serotonergic, noradrenergic, and dopaminergic pathways may be involved in the etiology of postural imbalance.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>The objective of this case report was to quantify, using computerized posturography, substitution with venlafaxine, and later levodopa, in a suspected case of postural instability with paroxetine.</p></div><div type="abstract" xml:lang="en"><p><b>CASE SUMMARY</b></p><p>Presented is an 86-year-old woman with frequent falls and a Parkinson-like syndrome of the lower limbs secondary to microvascular dementia. Paroxetine was gradually discontinued and exchanged for venlafaxine, 37.5 mg twice daily. Before and after medication changes, static posturography was performed under eyes open and closed conditions. Following 3 months of venlafaxine, the patient showed significant improvement from baseline, however, venlafaxine was then reduced to 37.5 mg at bedtime. Six months later, levodopa was introduced and further improvement was observed. It is possible that venlafaxine, which maintains a more balanced affinity for serotonin and norepinephrine transporters, may have provided postural benefit. Decreased sedation secondary to venlafaxine reduction may have elicited further improvements in addition to the increased lower limb functionality observed with levodopa.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>For patients on antidepressants, switching medications may be worthwhile in those with balance problems. The prudent addition of medications may also be an option.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21507731</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-7761</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of geriatric pharmacotherapy</Title><ISOAbbreviation>Am J Geriatr Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia.</ArticleTitle><Pagination><MedlinePgn>133-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjopharm.2011.03.002</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Postural instability is a concern in several neurologic conditions and also among the elderly. Dysfunction in serotonergic, noradrenergic, and dopaminergic pathways may be involved in the etiology of postural imbalance.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this case report was to quantify, using computerized posturography, substitution with venlafaxine, and later levodopa, in a suspected case of postural instability with paroxetine.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">Presented is an 86-year-old woman with frequent falls and a Parkinson-like syndrome of the lower limbs secondary to microvascular dementia. Paroxetine was gradually discontinued and exchanged for venlafaxine, 37.5 mg twice daily. Before and after medication changes, static posturography was performed under eyes open and closed conditions. Following 3 months of venlafaxine, the patient showed significant improvement from baseline, however, venlafaxine was then reduced to 37.5 mg at bedtime. Six months later, levodopa was introduced and further improvement was observed. It is possible that venlafaxine, which maintains a more balanced affinity for serotonin and norepinephrine transporters, may have provided postural benefit. Decreased sedation secondary to venlafaxine reduction may have elicited further improvements in addition to the increased lower limb functionality observed with levodopa.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For patients on antidepressants, switching medications may be worthwhile in those with balance problems. The prudent addition of medications may also be an option.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Groupe de recherche en analyse du mouvement etergonomie, Kinesiology, Laval University, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbeil</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pourcher</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Geriatr Pharmacother</MedlineTA><NlmUniqueID>101190325</NlmUniqueID><ISSNLinking>1876-7761</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003511">Cyclohexanols</NameOfSubstance></Chemical><Chemical><RegistryNumber>41VRH5220H</RegistryNumber><NameOfSubstance UI="D017374">Paroxetine</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>7D7RX5A8MO</RegistryNumber><NameOfSubstance UI="D000069470">Venlafaxine Hydrochloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003511" MajorTopicYN="N">Cyclohexanols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003936" MajorTopicYN="N">Diagnosis, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055806" MajorTopicYN="N">Microvessels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017374" MajorTopicYN="N">Paroxetine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004856" MajorTopicYN="N">Postural Balance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069470" MajorTopicYN="N">Venlafaxine Hydrochloride</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>03</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21507731</ArticleId><ArticleId IdType="pii">S1543-5946(11)00046-8</ArticleId><ArticleId IdType="doi">10.1016/j.amjopharm.2011.03.002</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Québec</li></region><settlement><li>Québec (ville)</li></settlement><orgName><li>Université Laval</li></orgName></list><tree><noCountry><name sortKey="Corbeil, Philippe" sort="Corbeil, Philippe" uniqKey="Corbeil P" first="Philippe" last="Corbeil">Philippe Corbeil</name><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name></noCountry><country name="Canada"><region name="Québec"><name sortKey="Mcdonald, Jaime" sort="Mcdonald, Jaime" uniqKey="Mcdonald J" first="Jaime" last="Mcdonald">Jaime Mcdonald</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PosturoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PosturoV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21507731
|texte= Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21507731" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PosturoV1
| This area was generated with Dilib version V0.6.37. |  |